May 13, 2022

View descriptionShare

Biotechs have seen their valuations take a plunge, triggering layoffs and pipeline cuts, but Big Pharma is not yet tempted to go on an M&A spree. CEOs of many of the world’s biggest pharma companies point out that biotech prices still have a way to drop before they become truly attractive buys. Also under discussion is Fierce's annual report on the highest paid biopharma R&D executives. This year, the list doesn’t look anything like it has in the past except for the fact that it continues to be comprised of white men. And the quarterly earnings calls are the buzz around the newsroom this week—but not in the way you might think.

To learn more about the topics in this episode:

The Top Line is produced by senior multimedia producer Teresa Carey with Editor-in-Chief Tracy Staton, Managing Editor Querida Anderson, senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.

  • Facebook
  • Twitter
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

  1. The Top Line

    31 clip(s)

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fie 
Recent clips
Browse 32 clip(s)